K.J. Harrison & Partners Inc grew its position in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX – Free Report) by 22.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 80,715 shares of the company’s stock after acquiring an additional 14,625 shares during the quarter. K.J. Harrison & Partners Inc owned 0.51% of BriaCell Therapeutics worth $476,000 at the end of the most recent reporting period.
Separately, K2 Principal Fund L.P. acquired a new position in BriaCell Therapeutics during the 3rd quarter worth approximately $156,000. 15.42% of the stock is owned by hedge funds and other institutional investors.
BriaCell Therapeutics Price Performance
NASDAQ:BCTX traded down $0.07 during trading hours on Friday, reaching $2.17. 36,051 shares of the stock were exchanged, compared to its average volume of 47,456. BriaCell Therapeutics Corp. has a twelve month low of $2.01 and a twelve month high of $7.59. The firm has a 50 day moving average of $2.82 and a 200 day moving average of $3.93. The stock has a market cap of $34.68 million, a PE ratio of -1.33 and a beta of 1.02.
BriaCell Therapeutics Profile
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.
See Also
- Five stocks we like better than BriaCell Therapeutics
- Technology Stocks Explained: Here’s What to Know About Tech
- MarketBeat Week in Review – 4/22 – 4/26
- What is a Stock Market Index and How Do You Use Them?
- 3 Stocks Leading the U.S. Agriculture Comeback
- 3 Ways To Invest In Coffee, Other Than Drinking It
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.